Wooden chest syndrome

Lore & Background

Wooden chest syndrome describes marked muscle rigidity—especially involving the thoracic and abdominal muscles—that is an occasional adverse effect associated with the intravenous administration of lipophilic synthetic opioids such as fentanyl. It can make ventilation difficult, and seems to be reversed by naloxone. Hypoxemia, hypertension, pulmonary hypertension, respiratory acidosis and increased intracranial pressure may supervene. One recent study hypothesized that chest wall rigidity might be at least partially responsible for some deaths related to intravenous injection of fentanyl, which increasingly is appearing in samples of heroin.

The pathophysiology is rooted in the binding of fentanyl to mu-opioid receptors in the central nervous system, triggering a cascade that culminates in severe muscle rigidity. Activation of noradrenergic and cholinergic pathways reduces chest wall compliance and increases muscle rigidity, leading to ineffective ventilation. Fentanyl's impact on the brainstem—particularly the respiratory centers—likely diminishes neural output to the respiratory muscles, exacerbating the rigidity and further compromising ventilation.

Diagnosis is typically made in a healthcare setting when a patient exhibits rapid-onset respiratory distress following fentanyl administration, with key indicators including sudden increase in airway pressures, hypoxia, and resistance to ventilation despite no apparent airway obstruction. There are no definitive laboratory or imaging tests for confirming WCS, so diagnosis relies heavily on clinical observation and the temporal relationship between fentanyl administration and symptom onset. Treatment begins with immediate cessation of fentanyl and administration of an opioid receptor antagonist such as naloxone, though naloxone may not fully alleviate muscle rigidity; respiratory support through mechanical ventilation is often required, and in severe cases neuromuscular blocking agents such as rocuronium can be administered.

Reader's Guide

Wooden chest syndrome is significant as a rare but serious adverse effect of fentanyl, a synthetic opioid widely used in medical settings for its rapid onset. Its prevalence is rising due to increasing use of fentanyl in both medical and recreational settings, and healthcare providers are becoming more aware of it, which may lead to better detection. The condition's association with fentanyl use in anesthesia and intensive care units highlights its relevance to healthcare settings. Cases have been reported in patients with various underlying conditions, including chronic obstructive pulmonary disease, chronic inflammatory demyelinating polyneuropathy, Guillain-Barré syndrome, and history of cerebral infarctions, underscoring the importance of careful monitoring and consideration of opioid-sparing techniques such as regional anesthesia to minimize risk in vulnerable patients. The prognosis varies on a case-by-case basis: with prompt diagnosis and effective treatment, most patients can recover fully without long-term complications, but delayed treatment or misdiagnosis can lead to severe outcomes including respiratory failure and potentially fatal consequences. The risk of recurrence is higher among individuals with opioid dependence or those undergoing repeated medical procedures requiring fentanyl administration, and prognosis tends to worsen with age.

Did You Know?

• Wooden chest syndrome can occur even with minimal amounts of fentanyl, as in a case where 50 μg caused complete body rigidity and apneic episodes.
• The condition is reversed by naloxone, though naloxone may not fully alleviate muscle rigidity.
• Patients with a history of cerebral infarctions are at a higher risk for developing wooden chest syndrome.